open access

Vol 15, No 3 (2018)
Review paper
Published online: 2018-09-24
Get Citation

Haloperidol and extrapyramidal symptoms: selected recent reports

Mariusz Racinowski, Wojciech Świerczyński, Kamil Leis, Aneta Rzym, Katarzyna Lipa, Przemysław Gałązka
Psychiatria 2018;15(3):160-164.

open access

Vol 15, No 3 (2018)
Prace poglądowe - nadesłane
Published online: 2018-09-24

Abstract

Antipsychotic therapy by haloperidol is used from many decades and it still occupies a key place in the treatment of
symptoms and prevention of recurrence of schizophrenia, mainly paranoid. It is also used in the treatment of bipolar
disorder and behavioral disorders as well. It is also effective as an antiemetic and in drug-resistant hiccups. It can be
used by both adults and children. The purpose of this review is to show selected articles describing methods, which may
reduce or even eliminate the risk of developing extrapyramidal syndrome, which is unavoidably accompanied by pharmacotherapy
with this drug. These symptoms are a frequent cause of withdrawal of psychiatric medications by patients
and thus, they are the reasons of the therapy’s failure. This review includes interpretations of articles that present the
results of research on new methods for predicting the risk of extrapyramidal syndrome caused by haloperidol treatment.
In this article we discussed predictive values of such factors as arterial blood lactate levels, creatine kinase activity, serum
selenium level or early antipsychotic effect. In search of new methods of prevention of the extrapyramidal syndrome, we
analyzed the effect of caffeine, naproxen and cystamine. Evaluation of the clinical and morphological effects of chronic
haloperidol administration has been based on results of patients who were suffering from paranoid schizophrenia from
a minimum of 30 years. The results of experiments comparing the new form of administration of haloperidol with the
previously known ones are also presented. The ideas presented in these works often require further clinical trials, which
may be the reason for exploring these problems.

Abstract

Antipsychotic therapy by haloperidol is used from many decades and it still occupies a key place in the treatment of
symptoms and prevention of recurrence of schizophrenia, mainly paranoid. It is also used in the treatment of bipolar
disorder and behavioral disorders as well. It is also effective as an antiemetic and in drug-resistant hiccups. It can be
used by both adults and children. The purpose of this review is to show selected articles describing methods, which may
reduce or even eliminate the risk of developing extrapyramidal syndrome, which is unavoidably accompanied by pharmacotherapy
with this drug. These symptoms are a frequent cause of withdrawal of psychiatric medications by patients
and thus, they are the reasons of the therapy’s failure. This review includes interpretations of articles that present the
results of research on new methods for predicting the risk of extrapyramidal syndrome caused by haloperidol treatment.
In this article we discussed predictive values of such factors as arterial blood lactate levels, creatine kinase activity, serum
selenium level or early antipsychotic effect. In search of new methods of prevention of the extrapyramidal syndrome, we
analyzed the effect of caffeine, naproxen and cystamine. Evaluation of the clinical and morphological effects of chronic
haloperidol administration has been based on results of patients who were suffering from paranoid schizophrenia from
a minimum of 30 years. The results of experiments comparing the new form of administration of haloperidol with the
previously known ones are also presented. The ideas presented in these works often require further clinical trials, which
may be the reason for exploring these problems.

Get Citation

Keywords

haloperidol, extrapyramidal symptoms, prediction, prevention

About this article
Title

Haloperidol and extrapyramidal symptoms: selected recent reports

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 3 (2018)

Article type

Review paper

Pages

160-164

Published online

2018-09-24

Bibliographic record

Psychiatria 2018;15(3):160-164.

Keywords

haloperidol
extrapyramidal symptoms
prediction
prevention

Authors

Mariusz Racinowski
Wojciech Świerczyński
Kamil Leis
Aneta Rzym
Katarzyna Lipa
Przemysław Gałązka

References (15)
  1. Dold M, Samara MT, Li C, et al. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015; 1: CD009831.
  2. Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther. 2007; 81(4): 586–594.
  3. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008; 23 Suppl 1: 15–26.
  4. Mosiołek A. Objawy pozapiramidowe w psychiatrii – diagnostyka i leczenie. Psychiatria. 2014; 11(3): 160–165.
  5. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157(4): 514–520.
  6. Rabe-Jabłońska J. Polekowe objawy pozapiramidowe. Farmakoterapia w Psychiatrii i Neurologii. 2001; 1: 57–71.
  7. Elmorsy E, Shahda M, Mahmoud EHM, et al. Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia. J Psychopharmacol. 2016; 30(1): 63–68.
  8. Khelfi A, Azzouz M, Abtroun R, et al. Antipsychotic-induced disorders: Reported cases and prospective study on muscle biomarkers after high exposure to haloperidol. Toxicol Appl Pharmacol. 2018; 352: 1–8.
  9. Rasmussen SA, Rosebush PI, Mazurek MF. The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects. J Clin Psychopharmacol. 2017; 37(1): 8–12.
  10. Arora D, Mudgal J, Nampoothiri M, et al. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. Metab Brain Dis. 2018; 33(4): 1045–1051.
  11. Zhang H, Zheng M, Wu M, et al. A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury. Genetics. 2016; 203(1): 599–609.
  12. Mutică M, Marinescu I, Militaru F, et al. Clinical and biological outcomes of prolonged treatment with haloperidol in schizophrenia. Rom J Morphol Embryol. 2016; 57(2): 477–481.
  13. El-Setouhy DA, Ibrahim AB, Amin MM, et al. Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in-vivo biodistribution. Eur J Pharm Sci. 2016; 92: 244–254.
  14. Ostuzzi G, Bighelli I, So R, et al. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017; 183: 10–21.
  15. Day JC, Kinderman P, Bentall R. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998; 97(1): 93–97.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl